Home›Research›Compare›BPC-157 vs CJC-1295 (without DAC)
Peptide ComparisonBPC-157 vs CJC-1295 (without DAC)
BPC-157
Body Protection Compound 157
Half-life: Under 30 minutes (plasma); no human PK data
635 providers listed
CJC-1295 (without DAC)
CJC-1295
Half-life: ~30 minutes
446 providers listed
BPC-157 and CJC-1295 (without DAC) target different goals — BPC-157 for tissue repair across tendon, muscle, nerve, and gut — most broadly studied recovery peptide, CJC-1295 (without DAC) for GH and IGF-1 elevation. They're compared here for reference, not as direct substitutes.
BPC-157
Evidence
Half-life
Under 30 minutes (plasma); no human PK data
CJC-1295 (without DAC)
Evidence
Half-life
~30 minutes
BPC-157 and CJC-1295 (without DAC) target different goals — BPC-157 for Tissue Repair, CJC-1295 (without DAC) for GH / IGF Axis. They're compared here for reference; there isn't a single “better” choice between them.
BPC-157
CJC-1295 (without DAC)
BPC-157
Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and…
Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approac…
+6 more
About BPC-157
BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. It appears to promote fibroblast migration and collagen synthesis, contributing to faster tissue remodelling. Animal studies suggest systemic effects via modulation of the dopaminergic and serotonergic systems, though human data remain limited.
About CJC-1295 (without DAC)
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
BPC-157
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
global — WADA
BPC-157 is on the WADA Prohibited List at all times (S0, Non-Approved Substances), effective 1 January 2022. It has no FDA approval and no adequate human clinical trial.
sourceCJC-1295 (without DAC)
Class-based (investigational)
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceBPC-157
GHK-Cu
Research suggests GHK-Cu and BPC-157 may produce complementary tissue repair and anti-inflammatory effects when combined. GHK-Cu is studied for copper-dependent collagen synthesis and antioxidant gene activation, while BPC-157 supports angiogenesis and growth factor expression.
TB-500
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
Anticoagulants / blood thinners
Research notes that BPC-157 promotes angiogenesis and may influence platelet and vascular function in healing models. Combined use with anticoagulant medications may warrant monitoring. Consult your prescriber before combining.
CJC-1295 (without DAC)
Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
BPC-157
CJC-1295 (without DAC)
Where to source these peptides
BPC-157
635 listed
Browse directory →
Providers offeringCJC-1295 (without DAC)
446 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). BPC-157 vs CJC-1295 (without DAC) — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/bpc-157/cjc-1295